Fate Therapeutics, Inc. (FATE)
NASDAQ: FATE · Real-Time Price · USD
1.300
+0.090 (7.44%)
At close: Jun 2, 2025, 4:00 PM
1.350
+0.050 (3.85%)
After-hours: Jun 2, 2025, 7:05 PM EDT
Fate Therapeutics Revenue
Fate Therapeutics had revenue of $1.63M in the quarter ending March 31, 2025, a decrease of -15.38%. This brings the company's revenue in the last twelve months to $13.34M, up 105.85% year-over-year. In the year 2024, Fate Therapeutics had annual revenue of $13.63M, down -78.55%.
Revenue (ttm)
$13.34M
Revenue Growth
+105.85%
P/S Ratio
10.71
Revenue / Employee
$73,674
Employees
181
Market Cap
149.02M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 13.63M | -49.90M | -78.55% |
Dec 31, 2023 | 63.53M | -32.77M | -34.03% |
Dec 31, 2022 | 96.30M | 40.45M | 72.44% |
Dec 31, 2021 | 55.85M | 24.41M | 77.66% |
Dec 31, 2020 | 31.43M | 20.75M | 194.33% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
FATE News
- 3 days ago - Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors - GlobeNewsWire
- 5 days ago - Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress - GlobeNewsWire
- 20 days ago - Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates - GlobeNewsWire
- 25 days ago - Fate Therapeutics: Suffering The Fate Of A Depressed Cell Therapy Sector - Seeking Alpha
- 4 weeks ago - Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting - GlobeNewsWire
- 7 weeks ago - Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE) - GlobeNewsWire
- 3 months ago - Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates - GlobeNewsWire